AbbVie Inc. / Kestrel Therapeutics, Inc.

KRAS-Mutant Solid Tumors (Pan-KRAS, including NSCLC, CRC, PDAC)

250K US cases/yr · $2.9B US Market · ~88% KRAS mutation prevalence in PDAC

Disease Overview

KRAS is the most frequently mutated oncogene in human cancer, present in approximately 20% of all malignancies. KRAS mutations cluster in pancreatic ductal adenocarcinoma (PDAC, ~88% prevalence), colorectal cancer (CRC, ~45-50%), and non-small cell lung cancer (NSCLC, ~30-35%), with smaller frequencies in endometrial, biliary tract, and other tumors. Mutated KRAS proteins are constitutively active GTPases that drive RAS-RAF-MEK-ERK and PI3K-AKT signaling, producing uncontrolled proliferation and survival. The mutational spectrum is heterogeneous: G12C predominates in NSCLC, G12D in PDAC and CRC, with G12V, G13D, Q61H, and others contributing to the long tail. Until 2021, KRAS was considered undruggable; Amgen's Lumakras (sotorasib) and Mirati/BMS Krazati (adagrasib) - both KRAS G12C-selective - opened the field but each addresses only ~13% of KRAS-mutant NSCLC and limited CRC. Unmet need is enormous: G12D, G12V, and pan-KRAS approaches are needed to reach the vast majority of KRAS-driven cancers, and resistance to G12C inhibitors emerges within 6-12 months. Five-year survival in KRAS-mutant metastatic PDAC is below 5%, in metastatic CRC ~15%, and in metastatic NSCLC ~10%, underscoring the need for next-generation pan-KRAS agents.

Competitive Landscape

The KRAS inhibitor field is in transition from G12C-selective first generation to pan-KRAS and G12D-selective next generation. Approved agents are Amgen Lumakras (sotorasib, KRAS G12C, NSCLC and CRC) and Mirati/BMS Krazati (adagrasib, KRAS G12C). The pan-KRAS leader is Revolution Medicines RMC-6236 (daraxonrasib, multi-RAS inhibitor in pivotal trials in PDAC and NSCLC, with promising early data and a market cap supported by best-in-class positioning). Other competitors include Revolution Medicines RMC-9805 (KRAS G12D), AstraZeneca/Jacobio JAB-23E73 ($2B Dec 2025 China deal for pan-KRAS), Mirati MRTX1133 (G12D), and BeiGene, Boehringer, and Novartis pipelines. Kestrel's KST-6051 enters as a potential best-in-class oral pan-KRAS inhibitor designed to bind KRAS in both GTP-bound active and GDP-bound inactive states while sparing HRAS/NRAS - the FALCON Phase 1 dosed first patient concurrent with the AbbVie deal in PDAC, CRC, NSCLC, and other KRAS-mutant malignancies. Five-to-ten years post-close, AbbVie's option exercise will hinge on whether KST-6051 demonstrates differentiated efficacy and tolerability versus Revolution Medicines RMC-6236 - the field benchmark - in early-line PDAC and NSCLC. If KST-6051 reads out competitively, AbbVie acquires a critical post-Humira oncology pillar; if not, the warrant structure preserves capital efficiency.